Close menu




September 11th, 2024 | 07:45 CEST

BioNTech, First Hydrogen, and TSMC with big announcements

  • Hydrogen
  • greenhydrogen
  • Biotechnology
  • Technology
  • semiconductor
Photo credits: pixabay.com

As we enter the final third of what has so far been a successful 2024 stock market year, uncertainties and volatility are increasing. Even the seemingly invincible chip giant Nvidia has lost around a quarter of its stock market value since its highs in mid-June. On the other hand, other companies that have fallen sharply in recent months have reported positive news that could herald a possible rebound.

time to read: 3 minutes | Author: Stefan Feulner
ISIN: TAIWAN SEMICON.MANU.ADR/5 | US8740391003 , First Hydrogen Corp. | CA32057N1042 , BIONTECH SE SPON. ADRS 1 | US09075V1026

Table of contents:


    BioNTech - Breakout

    With a price explosion of over 12%, BioNTech, which mutated into a stock market star during the COVID-19 pandemic, not only recaptured the USD 100 mark but also broke through the upward trend established at the end of March 2022. The buy signal generated should initially take BioNTech shares to the horizontal resistance area at around USD 117. The stock is receiving a tailwind from the relative strength index, which still has considerable room to run in the neutral area of 62, as well as the trend-following indicator MACD, which generated a buy signal at a low level.

    The reason for the price explosion is the fact that the Mainz-based company is carrying positive news about several product candidates in its suitcase to Spain. The Conference of the European Society for Medical Oncology will be held in Barcelona from September 13 to 17. This event attracts many European cancer researchers. BioNTech plans to present information on various compounds currently in development, paying particular attention to the antibody BNT327. This is to be used to treat various types of cancer.

    Analysts at JPMorgan are nevertheless skeptical ahead of the event. In a current study, the price target was left at USD 91.00, and the investment rating is "Underweight."

    First Hydrogen - Expansion into Europe

    The hydrogen innovator with offices in Vancouver, Montreal, and London is continuing to work on its global hydrogen strategy and is planning to expand into Europe with the opening of an office in Germany. Several international companies with expertise in renewable energy development, infrastructure construction, mergers & acquisitions, and fundraising have been commissioned to support the expansion. The aim is to enter the hydrogen ecosystem with its commercial vehicle powered by hydrogen fuel cells.

    In the UK, First Hydrogen has successfully completed several test drives in real road conditions with major fleet operators such as online giant Amazon. First Hydrogen's light commercial vehicles achieved record ranges of 630 km on a single tank. Analyses also showed that there was hardly any drop in performance at extreme temperatures.

    The outstanding test results also aroused great interest from Canada, where First Hydrogen plans to develop additional demo vehicles. Plans are also well advanced to build a vehicle assembly plant and a production facility for green hydrogen in Shawinigan, Quebec. From there, around 25,000 vehicles are to be produced annually for the North American market.

    In the course of the general market correction, First Hydrogen shares have also fallen to a level of CAD 0.40 in recent months. Given the positive outlook and the global hydrogen strategy, however, a significant rebound could be imminent.

    TSMC - Defying the peer group

    The chip industry, particularly NVIDIA shareholders, may have breathed a sigh of relief, thanks to the Taiwanese giant TSMC. After NVIDIA's weak outlook last week, analysts were concerned that the market had overestimated the durability of AI infrastructure spending.

    With a 33% increase in sales, TSMC was able to dispel these concerns. Sales reached around USD 7.8 million in August, a slowdown from the previous month's 45% growth. Analysts expect TSMC sales to increase by 37% in the third quarter. With August's results, TSMC appears to be on track to slightly exceed average sales forecasts for the third quarter, according to Bernstein. If September follows the seasonal average of the last eight years, revenue in third quarter 2024 could be 5% to 6% above guidance and consensus.

    More than half of the revenue for Taiwan's largest company, TSMC, is now generated by its high-performance computing segment, which is heavily benefiting from the rising demand in the field of artificial intelligence. TSMC is also the most important producer of the main processor for the iPhone.


    Taiwan Semiconductor's strong figures dispelled concerns about stagnation in AI infrastructure spending. Market experts are tipping positive news from BioNTech on several product candidates. First Hydrogen plans to expand into Europe by opening an office in Germany.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Stefan Feulner

    The native Franconian has more than 20 years of stock exchange experience and a broadly diversified network.
    He is passionate about analyzing a wide variety of business models and investigating new trends.

    About the author



    Related comments:

    Commented by Fabian Lorenz on October 22nd, 2025 | 07:15 CEST

    HYDROGEN IS ALIVE! Bloom Energy, thyssenkrupp nucera, and dynaCERT! 1,000% not enough?

    • Hydrogen
    • greenhydrogen
    • cleantech
    • renewableenergies

    Plug Power has gained nearly 500% since May, proving that hydrogen is very much alive. The applications may be different from what was expected in the hype a few years ago - more specific and niche-focused. Investors are speculating that hydrogen will benefit from the energy boom driven by artificial intelligence. The same applies to Bloom Energy, whose stock has exploded by 1,000% over the past year. dynaCERT is active in an exciting niche, offering conversion kits for diesel engines ranging from trucks to container ships. Initial sales successes give hope for more. Will emission certificates follow? And what is Germany's hydrogen hope, thyssenkrupp nucera, doing? It remains in the shadow of TKMS. Still, one analyst sees upside potential of around 50%.

    Read

    Commented by Armin Schulz on October 22nd, 2025 | 07:05 CEST

    Bitcoin soars: How Strategy, Nakiki, and BlackRock are benefiting from the new MiCA regulation on tokenization

    • Bitcoin
    • Tokenization
    • crypto
    • Digitization
    • Technology

    Bitcoin is reaching new record highs. The hashrate is exploding, and analysts are predicting prices of USD 250,000. At the same time, the EU is establishing clear rules for tokenization through MiCA. This unique combination of technological strength and regulatory clarity is unleashing unprecedented institutional interest. Three companies are strategically positioned to capitalize on this boom: Strategy, Nakiki, and BlackRock. Here, we take a closer look at how these companies have positioned themselves.

    Read

    Commented by Nico Popp on October 22nd, 2025 | 07:00 CEST

    Important piece of the puzzle in the fight against cancer: Vidac Pharma, Roche, Merck & Co.

    • Biotechnology
    • Biotech
    • Pharma
    • Cancer
    • Technology
    • Innovations

    The pharmaceutical market is enormous - and continues to grow. Market research institute Evaluate forecasts an increase to around USD 1.7 trillion by 2030, representing an annual growth rate of 7.7%. Oncology promises the highest sales, at around USD 300 billion. However, there is no single approach. Instead, new modalities and technologies such as antibody-drug conjugates (ADCs), cell and gene therapies, and radiopharmaceuticals are transforming the industry and gaining significant traction. One thing is clear: progress in the biotech sector is increasingly achieved through the combination of active ingredients and technologies. What role does the biotech company Vidac Pharma play in this?

    Read